BioMed Central Cancer
Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8776, and the mechanisms involved in the schedule dependence.
Montano, Ryan; Thompson, Ruth; Chung, Injae; Hou, Huagang; Khan, Nadeem; and Eastman, Alan, "Sensitization of Human Cancer Cells to Gemcitabine by the Chk1 Inhibitor MK-8776: Cell Cycle Perturbation and Impact of Administration Schedule in Vitro and in Vivo" (2013). Open Dartmouth: Faculty Open Access Articles. 578.